| Literature DB >> 23439651 |
Yongyu Xu1, Xiaoyuan Wei, Min Wang, Ru Zhang, Yanbin Fu, Mingzhe Xing, Qiuhong Hua, Xin Xie.
Abstract
The discovery of induced pluripotent stem (iPS) cells provides not only new approaches for cell replacement therapy, but also new ways for drug screening. However, the undefined mechanism and relatively low efficiency of reprogramming have limited the application of iPS cells. In an attempt to further optimize the reprogramming condition, we unexpectedly observed that removing c-Myc from the Oct-4, Sox-2, Klf-4, and c-Myc (OSKM) combination greatly enhanced the generation of iPS cells. The iPS cells generated without c-Myc attained salient pluripotent characteristics and were capable of producing full-term mice through tetraploid complementation. We observed that forced expression of c-Myc induced the expression of many genes involved in cell cycle control and a hyperproliferation state of the mouse embryonic fibroblasts during the early stage of reprogramming. This enhanced proliferation of mouse embryonic fibroblasts correlated negatively to the overall reprogramming efficiency. By applying small molecule inhibitors of cell proliferation at the early stage of reprogramming, we were able to improve the efficiency of iPS cell generation mediated by OSKM. Our data demonstrated that the proliferation rate of the somatic cell plays critical roles in reprogramming. Slowing down the proliferation of the original cells might be beneficial to the induction of iPS cells.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23439651 PMCID: PMC3617278 DOI: 10.1074/jbc.M112.403881
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157
Primers used for quantitative RT-PCR
| Genes | Sequences |
|---|---|
| β- | |
FIGURE 1.c-Myc omission from the mixture of Yamanaka boosts iPS cell generation. A, representative image of iPS (GFP+) colonies generated from 5000 MEFs infected with various combinations of Yamanaka factors. Uninfected MEFs served as negative control. The boxed areas in the left column are presented enlarged at the right. Scale bars, 7 mm. B and C, statistical analysis of the number of GFP+ colonies (B) and the percentage of GFP+ cells (C) per well shown in A. D, MEFs were infected with 4 factors with one of the factors in serial dilutions, and the percentage of GFP+ cells were analyzed by FACS. E, PCR analysis to confirm the absence of c-Myc in OSK-transduced MEFs. Uninfected MEFs served as a negative control and β-Actin was used as a loading control. *, p < 0.05; **, p < 0.01; ***, p < 0.001. F and G, representative image (F) or statistical analysis (G) of iPS (GFP+) colonies generated from MEFs with different passages infected with 3 or 4 factors. H, strategies employed in iPS cell generation. I, the number of GFP+ colonies generated with OSKM- or OSK-transduced MEFs in M/M or M/K conditions. ***, p < 0.001.
FIGURE 2.Pluripotency of iPS cells generated without c-Myc. A, genomic PCR analysis to confirm the absence of c-Myc integration in OSK-iPS colonies. Corresponding plasmids were used as positive control, whereas uninfected MEFs were used as negative control. B, alkaline phosphatase staining, GFP expression, and immunofluorescent staining of pluripotency markers SSEA-1 and Nanog in OSK-iPS clones. Scale bars, 50 μm. C, representative histogram from FACS analysis of surface SSEA-1 on three OSK-iPS clones. Cells stained with secondary antibody only served as control. D, quantitative PCR analysis of pluripotency genes and exogenous transgenes in OSK-iPS clones. mES cell line E14, MEF, and MEF infected with 4F for 4 days were used as controls. E, representative photos of chimeric mice generated from OSK-iPS cells and the agouti coat colored offspring of one male chimera.
Characterization of OSK-iPS in chimera formation and germline transmission
All three OSK-iPS cell lines exhibit high capacity in chimera contribution and germline transmission.
| OSK-iPS cell line | Blastocytes transplanted | Offspring | Chimera | Total F2 number (with dark coat) | Germline transmission |
|---|---|---|---|---|---|
| % | % | ||||
| #E | 32 | 9 | 8 (88.9%) | 28 (28); | 79.8 |
| 14 (14); | |||||
| 30 (30); | |||||
| 27 (7) | |||||
| #F | 20 | 5 | 5 (100%) | 20 (12); | 73.12 |
| 19 (2); | |||||
| 26 (26); | |||||
| 28 (28) | |||||
| #G | 50 | 8 | 6 (75%) | 20 (20); | 100 |
| 17 (17); | |||||
| 12 (12) |
FIGURE 3.MEFs without c-Myc overexpression display a slower proliferation rate at the initial stage of reprogramming. A, representative images of MEFs 2 days after the viral infection of 3 or 4 factors. Nuclei were visualized with DAPI staining (blue). Scale bars, 50 μm. B, proliferation rates of MEFs transduced with various combinations of factors at the initial stage of reprogramming (day 1–3) (*, p < 0.05; **, p < 0.01). C, the effect of each factor on MEF proliferation. MEFs were infected with 4 factors with one of the factors in serial dilutions, and the number of MEFs was analyzed at day 2. D, proliferation of MEFs infected with 3 or 4 factors monitored using CFSE labeling. CFSE histograms from one representative experiment is shown (n = 3). E, quantitative PCR analysis of the expression levels of the core components of the cell cycle machinery in MEFs 2 days after the infection of 3 or 4 factors (*, p < 0.05; **, p < 0.01; ***, p < 0.001). The expression level of each gene was normalized to that of β-Actin in the same sample and then normalized to MEFs without viral infection.
FIGURE 4.Higher proliferation rate of MEFs correlates with lower reprogramming efficiency. A and B, time course study of the proliferation rate of MEFs and the reprogramming efficiency with OSK and serially diluted c-Myc viruses. MEFs were transduced with OSK plus c-Myc in 5-fold serial dilutions (including zero concentration). The number of total cells (A) and the percentage of GFP+ cells (B) were monitored every other day during the reprogramming process. C, proliferation rates of two OSK-iPS and two OSKM-iPS clones. Cell numbers were normalized to the value obtained on day 1. D, quantitative PCR analysis of the expression levels of Cdk 1/2/4 in OSK or OSKM iPS clones. The expression level of each gene was normalized to that of β-actin in the same sample and then normalized to MEFs. E, characterization of cell death in OSK- or OSKM-mediated reprogramming using propidium iodide staining and FACS analysis. F and G, MEFs were infected with OSKM or OSK in combination with a Moloney murine leukemia virus 5′ LTR promoter-driven dsRed virus and seeded at different densities in a 96-well plate, the number of GFP+ dsRed− colonies were counted at day 14 (G), the number of dsRed+ cells were recorded at day 6, and the reprogramming efficiency (H) was calculated (number of GFP+ dsRed− colonies/number of dsRed+ cells). *, p < 0.05; **, p < 0.01; ***, p < 0.001.
FIGURE 5.Small molecules inhibiting cell proliferation improve iPS cell generation. Various anti-proliferative agents were added into the 4 factor-mediated iPS generation system from day 3 to 8, and representative images and statistical analysis of GFP+ colonies are presented. Meanwhile, the growth inhibition of MEFs by these chemicals was tested in the same culture conditions as used in reprogramming and cell growth was monitored with FACS analysis. A–C, the effect of p53 activators nutlin-3 (10 μm) and caylin-1 (10 μm) on iPS cell generation (A and B) and MEF proliferation (C). D–F, the effect of chemotherapy drugs aphidicolin (600 nm) and cisplatin (300 nm) on iPS cell generation (D and E) and MEF proliferation (F). G-I, the effect of kinase inhibitors targeting cell-cycle machinery, including aloisine A (100 nm), compound 52 (100 nm), and Cdk9 inhibitor II (100 nm), on iPS cell generation (G and H) and MEF proliferation (I) (*, p < 0.05; **, p < 0.01; ***, p < 0.001, or stated otherwise).
Small molecule enhancers on reprogramming and their effects on cell proliferation
| Small molecules | Molecular targets | Functions in reprogramming | Effects on cell proliferation |
|---|---|---|---|
| BIX-01294 | G9a histone methyltransferase (G9a HMTase) inhibitor | Promote reprogramming of MEFs and neural progenitor cells using OK ( | Suppress cancer cell proliferation ( |
| RG108 | DNA methyltransferase inhibitor | Promote reprogramming using OK with BIX ( | Displays antiproliferative properties against cancer cells with no detectable cytotoxic effects ( |
| Bay K8644 | Promote reprogramming using OK with BIX ( | Depend on concentration towards mouse spleen lymphocytes ( | |
| Parnate | Lysine-specific demethylase 1 inhibitor | Promote reprogramming of human primary keratinocytes using OK ( | Not directly addressed. |
| Kenpaullone | Inhibitor of GSK-3β, Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p35 | Promote reprogramming of MEFs without Klf-4 ( | Delay cell cycle progression on MCF10 A cells ( |
| Valproic acid | HDAC inhibitor | Promote reprogramming of MEFs using OSK or OSKM and human fibroblast using OS, OSK ( | Suppress cell proliferation in various cell types ( |
| Stimulate proliferation of hematopoietic stem cells ( | |||
| Trichostatin A | HDAC inhibitor | Improve reprogramming of MEFs ( | Inhibit cell proliferation in a variety of cancer cells ( |
| Suberoylanilide hydroxamic acid (SAHA) | HDAC inhibitor | Improve reprogramming of MEFs ( | Inhibit of cell proliferation and induce cell cycle arrest ( |
| 5-Azacytidine | DNA methyltransferase inhibitor | Promote reprogramming of MEFs ( | Inhibit cell proliferation of NIH-3T3 cells ( |
| Dexamethasone | Synthetic glucocorticoid | Acts with 5-azacytidine to promote reprogramming ( | Suppress EGF-stimulated proliferation of rat gastric epithelial cell. Suppress proliferation of C6 glioma cell and human bone marrow stromal cells ( |
| Wnt3a conditioned medium | Provide Wnt signaling | Promote reprogramming of MEFs using OSK ( | Promote proliferation of stem cells; continuous Wnt exposure resulted in a marked decrease in proliferation of MEFs ( |
| CHIR99021 | GSK3 inhibitor | Enable reprogramming of MEFs using OK ( | Antiproliferative against several tumor cell lines ( |
| A-83–01 | Inhibitor for the TGF-β pathway | Promote reprogramming of neonatal human epidermal keratinocytes using OK ( | No apparent affect on cell proliferation assessed in HM-1 cells. Block TGF-β-induced cell proliferation arrest ( |
| SB431542 | TGF-β inhibitor | Promote reprogramming of human fibroblasts ( | Stimulate proliferation of endothelial cells derived from embryonic stem cells ( |
| PD0325901 | MEK inhibitor | Inhibit proliferation of tumor cells ( | |
| Vitamin C | Alleviates senescence | Promote human and mouse fibroblast reprogramming ( | Promote proliferation ( |
| E-616452 (Repsox) | Inhibitor of the Tgfbr1 kinase | Promote reprogramming of MEFs in absence of Sox-2 ( | Induce G1/S arrest ( |
| Butyrate | Small-chain fatty acid | Promote reprogramming in the absence of either c-Myc or Klf4 ( | Inhibit proliferation in various tumor cells ( |
| LiCl | Affects several enzymatic activities | Enable reprogramming of MEFs with ( | Induce apoptosis in cancer cells ( |